Replies to post #163229 on Biotech Values

[DewDiligence]

There was some testing of ABT-450 with interferon, but not enough to form the basis of anything consequential. ABBV essentially put the program on hold until discovering that ABT-450 could form the backbone of an effective all-oral regimen.

[DewDiligence]

ENTA—As an addendum to #msg-89519033, here’s some ABT-450 + IFN data (from #msg-61757048):

At week 12, 92% of patients receiving ABT-450/r (ABT-450 with 100 mg of ritonavir to support once-daily dosing) in combination with…pegylated interferon alpha and ribavirin…achieved HCV RNA <25 IU/mL.

Not especially helpful, but there is it.